Ascletis Pharma’s Denifanstat Achieves Breakthrough in Acne Treatment

Ascletis Pharma, Inc. ( (HK:1672) ) has provided an update.

Ascletis Pharma Inc. announced that its Phase III trial of Denifanstat (ASC40), a first-in-class, once-daily oral fatty acid synthase (FASN) inhibitor for acne, met all primary and secondary endpoints, demonstrating significant efficacy and a favorable safety profile. This breakthrough provides a potential new treatment for acne, showing superior effectiveness compared to existing FDA-approved treatments, and highlights Ascletis’s commitment to advancing dermatological therapies.

The most recent analyst rating on (HK:1672) stock is a Hold with a HK$3.94 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.

More about Ascletis Pharma, Inc.

Ascletis Pharma Inc. is a biopharmaceutical company focused on developing innovative drugs for the treatment of various diseases. The company specializes in creating first-in-class therapies, particularly in the field of dermatology, with a market focus on conditions such as acne vulgaris.

Average Trading Volume: 6,408,289

Technical Sentiment Signal: Buy

Current Market Cap: HK$7.74B

For a thorough assessment of 1672 stock, go to TipRanks’ Stock Analysis page.